AT Bancorp’s bluebird bio BLUE Stock Holding History

AT Bancorp’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-201	Closed	-$409K	–	226
2018 Q2	$409K	Buy	+201	New	+$458K	0.05%	173

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AT Bancorp's BLUE Position: Q3 2018 in Review

AT Bancorp sold out of bluebird bio (BLUE) in Q3 2018, closing a stake of 201 shares — an estimated $409K sold.

AT Bancorp first reported a position in BLUE in Q2 2018 and held it in 1 quarter. The position peaked at $409K in Q2 2018. 288 funds tracked by Wall St. Rank hold BLUE as of Q3 2018.

AT Bancorp reported no remaining bluebird bio position as of Q3 2018 after selling out during the quarter.
AT Bancorp sold 201 bluebird bio shares in Q3 2018, an estimated $409K.
AT Bancorp first reported a position in bluebird bio in Q2 2018 and held it in 1 quarter.
AT Bancorp's bluebird bio position peaked at $409K in Q2 2018.
288 funds tracked by Wall St. Rank held bluebird bio as of Q3 2018.

Based on AT Bancorp's 13F filing for Q3 2018, filed 13 Nov 2018.